

Expression of placental growth factor mRNA in preeclampsia

Pooneh Nikuei¹ M.D., Minoo Rajaei² M.D., Kianoosh Malekzadeh^{1,3} Ph.D., Azim Nejatizadeh^{1,3} M.D., Ph.D., Fatemeh Mohseni¹ M.Sc., Fatemeh Poordarvishi¹ M.Sc., Nasrin ghashghaezadeh² M.D., Mehrdad Mohtarami⁴ B.Sc. Student.

1. Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
2. Fertility and Infertility Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
3. Department of Medical Genetics; Faculty of Medicine; Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
4. Biology Department, Long Island University, Post Campus, New York, USA.

Minoo Rajaei and Kianoosh Malekzadeh are equal corresponding author.

Corresponding Author:

Minoo Rajaei, Fertility and Infertility Research Center, Shariati Hospital; Hormozgan University of Medical Sciences, Bandar Abbas, Iran

Tel: (+98) 76 33354939

Email: rajaei_minoo@yahoo.com
Kianoosh Malekzadeh, Molecular Medicine Research Center, Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

Email: kianoosh.malekzadeh@hums.ac.ir

Email: (+98) 76 33354939

Received: 10 December 2016

Revised: 5 January 2017

Accepted: 16 January 2016

Abstract

Background: Preeclampsia (PE) is a serious complication of pregnancy with hallmarks of incomplete placentation, placental ischemia and endothelial dysfunction. Imbalance between vascular endothelial growth factor (VEGF), placenta growth factor (PlGF) and their receptors play important role in pathophysiology of PE.

Objective: This study was aimed to assess PlGF mRNA expression in placenta of women affected with PE.

Material and Methods: In this cross-sectional study, expression of PlGF mRNA was evaluated in 26 mild PE cases, 15 severe preeclamptic women and 20 normotensive controls. Patients were sub-classified as early onset PE (9) and late onset (32). After RNA extraction, PlGF expression was quantified with qRT-PCR.

Results: The results of PlGF mRNA expression between mild-severe, and early-late onset PE patients showed no statistically significant difference compared with the control group ($p=0.661$, $p=0.205$ respectively).

Conclusion: Despite we found no distinct differential expression of PlGF mRNA in placental tissue of PE patients compared with control women, but according to decreased level of this angiogenic factor in PE even before clinical onset of the disease, determining molecular mechanisms related to reduced secretion of PlGF into the maternal circulation may be useful for future therapeutics.

Keywords: Preeclampsia, Expression, Placental growth factor, Endothelial dysfunction.

This article extracted from Doctoral dissertation. (Pooneh Nikuei)

Introduction

Preeclampsia (PE) is a serious complication of pregnancy and main cause of maternal death which causes almost 15-20% of pregnancy-related mortalities (1). PE is characterized by hypertension and proteinuria after 20th wk of gestation; a multisystem disease affecting liver, kidneys, hematological and nervous system causing cerebral edema, seizures, and even maternal death (2). Currently, there is no definite treatment for PE and the only definite management is termination of

pregnancy, delivery of the placenta and fetus which enhances risk of disability and death for baby especially in severe and early onset cases (3, 4). Risk factors and past obstetrics history alone cannot predict PE, and for this reason, identification of high risk women for developing PE is important (5). Incomplete placentation, placental ischemia, and endothelial dysfunction are recognized as the main pathogenesis and hallmarks of PE (6). Angiogenesis which is essential for trophoblastic invasion and uteroplacental vascularization is disrupted in PE patients but molecular mechanisms are not completely

understood (7, 8). For effective angiogenesis, vasculogenesis and adequate placental development in pregnancy, a balance between vascular endothelial growth factor (VEGF), placenta growth factor (PlGF) and their receptors are crucial (9, 10). VEGF-A acts through enhancing angiogenesis as an important growth factor for endothelium (8).

In addition to VEGF-A, PlGF induces angiogenesis and affects proliferation and migration of endothelial cells (11). PlGF belongs to VEGF family and is a pro-angiogenic factor which is closely related to VEGF-A (12). Despite existence of some angiogenic growth factors in placenta, PlGF expression has a great importance (13). In human PlGF gene is mapped to chromosome 14q24 (14). PlGF protein which shows a main homology with VEGF, is predominantly expressed in trophoblast cells of placenta and its aberrant expression could lead to insufficiency in placental vasculature (11).

VEGFR-1 (also known as Flt-1) and VEGFR-2, (also known as KDR) are two principal receptors for VEGF-A and PlGF. VEGF-A acts through both FLT1 and KDR while PlGF acts only through FLT1, and not through KDR. VEGF-A controls angiogenesis up to 25 weeks of gestation and from that time to end of pregnancy angiogenesis is regulated by PlGF (12). It is likely that PlGF displaces VEGF from VEGFR1 and pushes VEGF for binding to VEGFR2 which has kinase activity ten-fold more than VEGF1 to enhance angiogenesis (15). Also, it is proposed that PlGF could increase maturation of uterine natural killer cells for enhancing trophoblastic invasion (16).

Actually, pro-angiogenic proteins such as VEGF and PlGF, which are associated with adequate vascular endothelial homeostasis, are antagonized by sFlt-1 (17). Animal studies showed that increased levels of anti-angiogenic proteins like sFlt-1 cause symptoms including proteinuria, hypertension, hematologic abnormalities, cerebral edema, and fetal growth restriction which are observed in human preeclampsia (18-20). Due to shallow invasion and abnormal placentation which leads to hypoxia, anti-angiogenic factors like sFlt-1 are released from placenta and neutralize VEGF and PlGF mediated signaling leading to endothelial dysfunction in PE patients (15). Mechanisms which enhance angiogenesis and vascular

remodeling in uteroplacental unit are not completely understood (8). Many molecular pathways are considered to be involved in placentation defects like PE, but among them VEGF family mediated angiogenic pathway is known to play a key role (12). PlGF produced by placenta is released in maternal circulation (8). In normal pregnant women, PlGF level increases remarkably from first trimester and reaches to peak level at 28-30 wk of gestation and then decreases continuously from late second trimester to term. Most of studies about PlGF in PE discussed circulating levels in serum (21, 22).

To the best of our knowledge, most studies related to mRNA expression of VEGF family in PE have concentrated on VEGFA and few studies are about PlGF mRNA expression in PE. Therefore, this study was aimed to evaluate the PlGF expression in placenta tissue of women affected to PE.

Materials and methods

Participants of this cross-sectional study were 41 women affected with PE and 20 term healthy pregnant women from two women hospitals in south of Iran. The sample size was calculated using G*Power software. The study was conducted from September 2014 to November 2015. In PE women, 26 had mild PE and severe form of disease was seen in 15 cases. These women also were classified as early onset PE (n=9) and late onset (n=32).

Women affected with PE (18-40 yr old) were included as case group and normal term pregnant women at the same gestational age were participated as control group. Women with diabetes mellitus, renal disease, collagen vascular diseases, chronic or gestational hypertension were excluded from this study. PE was defined as gestational hypertension (systolic pressure >140 mmHg or diastolic blood pressure >90 mmHg on two or more occasions after gestational wk 20) with proteinuria (>0.3 g/day).

If more than one of the following criteria were present, PE was defined severe: (i) severe gestational hypertension means systolic pressure >160 mm Hg or diastolic blood pressure >110 mm Hg on two or more occasions after gestational wk 20, (ii) severe proteinuria means protein \geq 5 gr in a 24 hr urine specimen, (iii) oliguria, (iv) cerebral or visual disturbances, (v) pulmonary edema or

cyanosis, (vi) epigastric or right upper-quadrant pain, (vii) impaired liver function, (viii) thrombocytopenia or (ix) fetal growth restriction (23). PE was also classified to early-onset (<34 wk of gestation) and late-onset (≥34 wk) (24).

Placental tissues biopsies (2 cm) were collected immediately after delivery near umbilical cord insertion and were put in RNAlater (Qiagen, Germany) and stored at -80°C until used. Total RNA was extracted from 100 mg of placental tissue biopsies using TRIZOL Isolation Reagent (Sigma-Aldrich, INC) according to the manufacturer's instructions. RNA contaminants were removed by treatment with the RNase-free DNase-I (Thermo Scientific, USA). First RNA was treated with 1µl DNase-I in 37°C for 30 min and then after adding 1µl 50mM EDTA, it was incubated in 65°C for 10 min to inactivate DNase. RNA quality and quantity were evaluated by agarose gel electrophoresis and NanoDrop ND-1000 spectrophotometer (Thermo Scientific, USA).

Quantitative RT-PCR

For each sample, 2µg of RNA was reverse transcribed to cDNA using Revert Aid TM First Strand cDNA Synthesis Kit (Fermentas, Canada) using random hexamer primer and according to the manufacturer's protocol. Quantitative RT-PCR was done by real-time PCR machine (Corbett Rotor-Gene 6000 Australia). Primers displayed in table I and Syber Green-Master Mix (Takara syber premix ex taq, Japan) were used for qRT-PCR. β-Actin was used as endogenous control for normalization of the raw data. Reactions were carried out in 20 µL of mixture with 2 µL cDNA, master mix 2X, ROX dye 50X and 10 pmol of each primer pairs for PIGF and β-actin. The thermal cycling conditions were initial denaturation at 95°C for 30 sec with 40 cycles of denaturation at 94°C for 5 sec, annealing at 59°C for 15 sec, extension at 72°C for 30 sec. 2^{-ΔΔCt} method was used for Analysis of Relative Gene Expression.

Ethical consideration

Informed written consent was obtained from the enrolled subjects for placental tissue collection under the protocols approved by the Ethical Committee of Hormozgan University of Medical Sciences, Hormozgan, Iran.

Statistical analysis

All data analyses were performed using Graphpad prism software (version 5.0) (GraphPad Software Inc., San Diego, CA). Based on Kolmogorov-Smirnov test, data did not have normal distribution and were compared using Kruskal-Wallis test. P<0.05 was considered significant.

Results

Mean maternal age in PE patients was 27.83±5.89 year and 26.85±4.84 yr in controls which the difference between two groups was not statistically significant (p=0.816) and shows a matching between case and control group. Also mean body mass index (BMI) was 23.82±3.88 in case group and 23.31±3.49 in control group with no significant difference (p=0.385). Placental weight was significantly reduced in PE group (p<0.001). 14.6% of women in PE group had history of PE in their previous pregnancies. Clinical characteristics are represented in table II.

Although an up-regulation in PIGF mRNA was observed in patients compared with the control women, it was not statistically significant (p=0.227). The results of PIGF mRNA expression between mild, severe and control group showed no statistically significant difference (p=0.661). Patients affected with mild and severe PE showed approximately the same expression in PIGF mRNA level. Also, mRNA expression for PIGF between early onset, late onset and control group showed no statistically significant difference (p=0.205), although an upregulation was observed in late onset patients compared with control women which was not significant. Results are shown in figures 1-3.

Table I. Characteristics of primers used in quantitative real-time PCR

Gene	Sequence of primers 5'→3'	Size (bp)	An. Temp. (°C)
PIGF	F GGCTGTTCCCTTGCTTCCT	110	59
	R TACCACTTCCACCTCTGACGA		
β-actin	F GCCTTTGCCGATCCGC	90	58
	R GCCGTAGCCGTTGTGCG		

An. Temp: annealing temperature

F: forward primer

R: reverse primer

PIGF: Placental growth factor

β-actin: beta Actin

PCR: polymerase chain reaction

Table II. Clinical characteristics of PE patients and control group

Parameter	PE (41)	Controls (20)	P-value
Maternal age (yr)	27.83 ± 5.89	26.85 ± 4.84	0.816
Placental weight (gr)	427 ± 85.04	609 ± 49.41	<0.001
BMI before pregnancy (kg/m ²)	23.82 ± 3.88	23.31 ± 3.49	0.385
Previous PE			
yes	6 (14.6%)	0 (0.0%)	
no	35 (85.4%)	20 (100.0%)	----
Severity			
Mild	26 (63.5%)	0	----
Severe	15 (36.5%)		
Onset Time			
Early	9 (22%)	0	----
Late	32 (78%)		

Results are represented as either mean ± SD or N (%). P<0.05 is considered to be significant.
 BMI: Body Mass Index PE: preeclampsia




Figure 1. PIGF mRNA expression among patients with PE in comparison with control group. An up-regulation in PIGF mRNA was observed in patients compared to normal women which was not significant. Data are presented as means ± S.E.M and analyzed using Mann–Whitney U-test. No significant statistical difference was observed between study groups.




Figure 3. PIGF mRNA expression among Patients with early and late onset PE in comparison with control group(B). Data are presented as means ± S.E.M and analyzed using Kruskal Wallis test. No significant statistical difference was observed between study groups.




Figure 2. PIGF mRNA expression among Patients with mild and severe PE in comparison with control group(A). Data are presented as means ± S.E.M and analyzed using Kruskal Wallis test. No significant statistical difference was observed between study groups.

Discussion

PIGF is highly expressed in placenta in all gestational stages. It is suggested to control growth and differentiation of trophoblastic cells and proposed to have role in trophoblast invasion into the maternal decidua (14). In PE patients, the circulating levels of PIGF decreases even several weeks prior to clinical symptoms of PE (25). Polliotti and coworkers reported decreased levels of PIGF in women affected to severe early onset PE (26). Schmidt and coworkers studied about angiogenic and antiangiogenic factors in PE and reported significantly lower levels of PIGF than normotensive pregnant women (27).

Shibata and coworkers reported lower levels of PIGF in serum samples of women affected to PE compared with normal controls (28). Meanwhile most studies related to sFlt-1 level in pregnancy shows elevated levels in peripheral blood of women with PE (18, 29). Decreased circulating PIGF level which is

observed in PE patients could be explained by antagonising by sFlt-1 as a potent anti-angiogenic factor.

Our results showed no significant difference in mRNA expression in PE patients compared with normal controls. Only a few studies reported mRNA alterations in patients affected to PE (12, 29, 32). Our results are in accordance with the findings of previous studies which reported no significant difference between the level of PIGF mRNA expression in PE women compared to normal controls (8, 30, 31). Tsatsaris and coworkers studied about dysregulation in the VEGF family in PE and reported no difference in PIGF mRNAs expression among the early onset severe PE patients and healthy controls (8).

TOFT and colleagues worked on expression of genes which regulate angiogenesis in PE including PIGF in placentas from preeclamptic women by whole-genome microarray and reported no difference between this group and controls (30). Also Pramatiarta and coworkers reported no difference between expression of cell-free mRNA of PIGF between serum of severe preeclamptic women and those with normal pregnancy (31).

Our findings disagree with some studies reporting decreased expression of PIGF mRNA in PE patients (12, 29, 32). Andraweera and coworkers; reported reduced expression of PIGF mRNA in placental of PE patients (12). Maebayashi and colleagues reported a significant decrease in PIGF mRNA in placenta of PE patients compared to the controls (29). Purwosunu and coworkers studied about the expression of genes related to angiogenesis in blood of preeclamptic women and the results of their study showed reduced expression of PIGF mRNA (32).

Hongling and colleagues reported lower levels of PIGF transcription in PE placenta compared to normal controls (33). Also, Shibata and coworkers assessed PIGF concentration in placental villous homogenates by ELISA and reported it in patients about half that of the controls (28). Semczuk and coworkers studied about expression of genes coding for proangiogenic factors in women affected to PE and reported higher levels of PIGF transcription in PE patients (34). This study is the only one which reports up-regulation of PIGF mRNA in placenta of PE patients.

Although most studies about circulating PIGF in PE showed decreased levels even

several weeks before the onset of PE, but there is an inconsistency about PIGF mRNA expression in PE. PIGF expression could be regulated at a posttranscriptional level, which explains the inconsistent results between its transcripts and protein levels (14). For better understanding of molecular mechanism of this disease, more researches with larger sample sizes and different ethnicities are needed to elucidate exact role of PIGF mRNA in PE.

Conclusion

In conclusion, although we did not find any significant difference in placental PIGF mRNA expression in PE patients compared to control women, studies about molecular mechanisms responsible for regulating expression of PIGF in trophoblastic cells could lead to new steps towards molecular aspects of PE.

Acknowledgments

We are grateful to women who participated in this study. This research was financially supported by Research Vice-Chancellor of Hormozgan University for Medical Science (HUMS), Hormozgan, Iran, gratefully acknowledged.

Conflict of interest

The authors report no conflicts of interest.

References

1. Nishizawa H, Ota S, Suzuki M, Kato T, Sekiya T, Kurahashi H, et al. Comparative gene expression profiling of placentas from patients with severe preeclampsia and unexplained fetal growth restriction. *Reprod Biol Endocrinol* 2011; 9: 107.
2. Perucci LO, Gomes KB, Freitas LG, Godoi LC, Alpoim PN, Pinheiro MB, et al. Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia. *PLoS One* 2014; 9: e97632.
3. Kaitu'u-Lino T, Hastie R, Cannon P, Nguyen H, Lee S, Hannan N, et al. Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14. *Placenta* 2015; 36: 932-937.
4. Karimi S, Yavarian M, Azinfar A, Rajaei M, Azizi Kootenae M. Evaluation the frequency of factor V Leiden mutation in pregnant women with preeclampsia syndrome in an Iranian population. *Iran J Reprod Med* 2012; 10: 59-66.
5. Wu P, van den Berg C, Alfirevic Z, O'Brien S, Röthlisberger M, Baker PN, et al. Early pregnancy biomarkers in pre-eclampsia: a systematic review and meta-analysis. *Int J Mol Sci* 2015; 16: 23035-23056.
6. Chung J-Y, Song Y, Wang Y, Magness RR, Zheng J. Differential expression of vascular endothelial growth

- factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. *J Clin Endocrinol Metab* 2004; 89: 2484-2490.
7. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. *J Clin Endocrinol Metab* 2004; 89: 770-775.
 8. Tsatsaris V, Goffin F, Munaut C, Brichant J-F, Pignon M-R, Noel A, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. *J Clin Endocrinol Metab* 2003; 88: 5555-5563.
 9. Kar M. Role of biomarkers in early detection of preeclampsia. *J Clin Diagn Res* 2014; 8: BE01-4.
 10. Tripathi R, Rath G, Jain A, Salhan S. Soluble and membranous vascular endothelial growth factor receptor-1 in pregnancies complicated by preeclampsia. *Ann Anat Anat Anzeiger* 2008; 190: 477-489.
 11. Torry DS, Hinrichs M, Torry RJ. Determinants of placental vascularity. *Am J Reprod Immunol* 2004; 51: 257-268.
 12. Andraweera P, Dekker G, Laurence J, Roberts C. Placental expression of VEGF family mRNA in adverse pregnancy outcomes. *Placenta* 2012; 33: 467-472.
 13. Welch PC, Amankwah KS, Miller P, McAsey ME, Torry DS. Correlations of placental perfusion and PIGF protein expression in early human pregnancy. *Am J Obstet Gynecol* 2006; 194: 1625-1629.
 14. De Falco S. The discovery of placenta growth factor and its biological activity. *Exp Mol Med* 2012; 44: 1-9.
 15. Furuya M, Kurasawa K, Nagahama K, Kawachi K, Nozawa A, Takahashi T, et al. Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia. *J Pregnancy* 2011; 2011: 123717.
 16. Tayade C, Hilchie D, He H, Fang Y, Moons L, Carmeliet P, et al. Genetic deletion of placenta growth factor in mice alters uterine NK cells. *J Immunol* 2007; 178: 4267-475.
 17. Rana S, Powe CE, Salahuddin S, Verloren S, Perschel FH, Levine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. *Circulation* 2012; 125: 911-919.
 18. Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. *New Eng J Med* 2004; 350: 672-683.
 19. Lu F, Longo M, Tamayo E, Maner W, Al-Hendy A, Anderson GD, et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. *Am J Obstet Gynecol* 2007; 196: 396. e1-e7.
 20. Maynard SE, Min J-Y, Merchan J, Lim K-H, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest* 2003; 111: 649-658.
 21. Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, Sibai BM. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. *Am J Obstet Gynecol* 2000; 183: 1554-1557.
 22. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. *J Matern Fetal Neonat Med* 2008; 21: 9-23.
 23. Practice ACoO. Practice bulletin# 33: diagnosis and management of preeclampsia and eclampsia. *Obstet Gynecol* 2002; 99: 159-167.
 24. Schaarschmidt W, Rana S, Stepan H. The course of angiogenic factors in early-vs. late-onset preeclampsia and HELLP syndrome. *J Perinatal Med* 2013; 41: 511-516.
 25. Louwen F, Muschol-Steinmetz C, Reinhard J, Reitter A, Yuan J. A lesson for cancer research: placental microarray gene analysis in preeclampsia. *Oncotarget* 2012; 3: 759-773.
 26. Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. *Obstet Gynecol* 2003; 101: 1266-1274.
 27. Schmidt M, Dogan C, Birdir C, Kuhn U, Gellhaus A, Kimmig R, et al. Placental growth factor: a predictive marker for preeclampsia? *Gynäkologisch-geburtshilfliche Rundschau* 2009; 49: 94-99.
 28. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. *J Clin Endocrinol Metab* 2005; 90: 4895-4903.
 29. Maebayashi A, Yamamoto T, Azuma H, Kato E, Kuno S, Murase T, et al. PP121. Expression of PIGF, sFlt, MTF-1, HO-1 and HIF-1 alpha mRNAs in preeclampsia placenta and effect of preeclampsia sera on their expression of choriocarcinoma cells. *Pregnancy Hypertens* 2012; 2: 304-305.
 30. Toft JH, Toft JH, Lian IA, Tarca AL, Erez O, Espinoza J, et al. Whole-genome microarray and targeted analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PIGF) in placentas from preeclamptic and small-for-gestational-age pregnancies. *J Matern Fetal Neonat Med* 2008; 21: 267-273.
 31. Pramartita AY, Mose J, Effendi JS, Krisnadi SR, Anwar AD, Fauziah PN, et al. Correlation between cell-free mRNA expressions and PLGF protein level in severe preeclampsia. *BMC Res Notes* 2015; 8: 208.
 32. Purwosunu Y, Sekizawa A, Yoshimura S, Farina A, Wibowo N, Nakamura M, et al. Expression of angiogenesis-related genes in the cellular component of the blood of preeclamptic women. *Reprod Sci* 2009; 16: 857-864.
 33. Hongling S, Hongyu L, Hanping C, Yuzhen G, Ming Z, Xiaoyan X, et al. Analysis of placental growth factor in placentas of normal pregnant women and women with hypertensive disorders of pregnancy. *J Huazhong Univ Sci Technol* 2006; 26: 116-119.
 34. Semczuk M, Borczynska A, Bialas M, Rozwadowska N, Semczuk-Sikora A, Malcher A, et al. Expression of genes coding for proangiogenic factors and their receptors in human placenta complicated by preeclampsia and intrauterine growth restriction. *Reprod Biol* 2013; 13: 133-138.